JaredGollobMD

specialization is Internal Medicine - Hematology & Oncology at Duke University Medical Ctr

Are you Dr. Gollob?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. Jared Gollob, MD is a hematologist in Durham, North Carolina. He is currently licensed to practice medicine in Massachusetts.

PubMed

2 citations
IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers.
Alice McDonald, Rahul Karnik, Veronica Campbell, Jeff Davis, Sara Chavoshi
The Journal of Investigative Dermatology. 2024-07-29
37 citations
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
Teresa Coelho, David H. Adams, Isabel Conceição, Márcia Waddington-Cruz, Hartmut Schmidt
Orphanet Journal of Rare Diseases. 2020-07-08
14 citations
DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis.
Ola Akinboboye, Keyur B. Shah, Alberta L. Warner, Thibaud Damy, Herman A. Taylor
Amyloid. 2020-05-26

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253May 19th, 2023
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical TrialsDecember 14th, 2022
Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual MeetingMay 3rd, 2021
Join now to see all